A meta-analysis of adult patients with type 2 diabetes showed that SGLT2 inhibitors use was associated with a decrease in body weight of 2.01 kg (95% CI: −2.18 to −1.83 kg) compared to baseline (45). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.